Observed arrival · 2026-10-18
Allkure’s ALK+ patient registry
A nonprofit project presents aggregated data on ALK+ lung cancer and invites patients to contribute updates to an international registry.
- For
- People with ALK+ lung cancer
- Worth noticing
- The first-line lorlatinib comparison is labeled n=17, and the site cautions that this sample is too small for stable conclusions.
Field notes
Allkure attributes its 572-person sample to ten public cohorts and separately states a goal of reaching 10,000 patients; the displayed registry counter currently reads zero. Its pages describe a self-created code rather than collecting a name, birth date, or city, followed by a 10–15-minute questionnaire and short updates after checkups or treatment changes. Some displayed analysis is explicitly limited: the first-line lorlatinib subgroup with available data is n=17, which the site says is too small for stable conclusions.
Observed signals
Read the marks
Editorial observations of this landing page, not a rating.
One card from the complete issue